It was also shown that CD133+ glioma stem cells from in vitro cultured neurospheres display elevated FADS1 and FADS2 activities (41) and that SCD and FADS2 exhibit spatial heterogeneity with higher expression in the peritumoral area (42). This evidence concerns the gene FADS1 and central nervous system cancer.